October 1985, 57 consultant neurologists (about one third of the total in the United Kingdom and Eire) working in 33 centres, recruited patients they thought had had a recent transient ischaemic attack (TIA) or minor ischaemic stroke (definitions of events are given below). Although CT was not widely available at the time, the vast majority of such minor strokes were presumably ischaemic and not due to primary intracerebral haemorrhage. Our intention was to avoid randomising patients less than 40 years old; those whose last cerebrovascular event had occurred more than three months earlier; those who had previously experienced a disabling major stroke; those whose attacks were definitely due to something other than arterial thromboembolism (migraine, hypoglycaemia, anaemia, polycythaemia rubra vera, cardiac arrhythmia, arteritis), but to include patients with potential cardiac sources of embolism who were not anticoagulated. We also excluded patients that were likely to experience adverse effects from aspirin-that is, previous allergy or intolerance, previous abnormal bleeding, alcoholism, chronic renal failure, peptic ulceration in the previous three years. Finally tablets; two tablets were to be taken in the morning and two in the evening (preferably with or after food) and each pair of tablets was specifically labelled by the day of the week and whether it was to be taken in the morning or evening. At first, aspirin and lactose cellulose and ethylcellulose film. In 1982 Eli Lilly started supplying enteric coated aspirin and lactose placebo for those patients unable to tolerate the plain trial tablets; the excipients consisted of starch, povidone, amberlite XD88, microcystalline cellulose granular 102 and magnesium stearate. In 1984 the plain tablet manufacture was taken over by Beecham Products and they were no longer film coated. Patients who were randomised to "high dose" aspirin received two 300 mg tablets twice daily, those randomised to "low dose" aspirin received two 150 mg aspirin tablets in the morning and the two evening tablets were placebo, and those randomised to "placebo" received two placebo tablets twice daily.
Each four month patient pack contained a leaflet giving information on when to take the medication, if tablets were missed not to take them the following day but to leave them in the packet, and to avoid non trial aspirin. It also included a container for urine collection for compliance testing (see below). Patients who complained of indigestion were advised to omit the evening pair of tablets. If they still complained of indigestion, they were told to take just one of the two morning tablets. If these stepdowns failed they were advised to transfer to enteric coated trial medication, four tablets a day and then-if necessary-to try reducing to one morning tablet daily. In this way we maintained as many patients as possible on, or as near to, their allocated treatment for as long as possible. Even if medication had to be stopped this was not necessarily permanent. Even if it was, the patients continued on follow up.
Follow up
Patients were seen every four months until after the scheduled end of the trial (30 September 1986), their prior death or emigration. If they could not, or would not, come to the neurological clinics, follow up was continued by postal or telephone contact with their general practitioners. In addition, each patient was flagged with the Office of Population Censuses and Surveys so that we received a death certificate in the event of their death. All the surviving patients were reviewed after the 30 September 1986. This was to ensure that all important events had been recorded and to inform the patients of the interim trial results (but not of their own treatment as the collaborators were still "blind" at that time).
Analysis of major events
In 1979 we originally envisaged the analysis would be of time to "non fatal major stroke, non fatal myocardial infarction, vascular death or non vascular death" taken as a composite event in a conventional log rank survival analysis.3 In 1984, without reference to the trial data, we decided that the analysis should include survival free of disabling stroke, whilst definitely non-vascular deaths should be censored. This was because we were concerned that aspirin, by virtue of its anti- For all reported major events (major stroke, myocardial infarction and death) the hospital medical records were reviewed, (as were the general practitioner's medical notes, if required) by CW who was blind to treatment allocation throughout the trial). A brief summary was made of the clinical, investigation and postmortem examination details (if performed). Death certificate diagnoses were only accepted if no other information was available. This summary was sent to the relevant collaborating neurologist for checking and then to the clinical audit committee. All the events were again reviewed by this committee after the end ofthe trial and a final decision made on how they should be coded, again blind to treatment allocation.
Adverse effects and compliance At each four monthly follow up visit the patients were asked about any adverse effects and if they had been taking the trial medication regularly, irregularly or not at all. If the trial medication was irregular or had stopped, the reason(s) was ascertained. In addition, the patients were asked to bring a morning urine sample (without telling them the reason) which was analysed, blind to treatment allocation, for aspirin using a modification of the ferric chloride test. The result was recorded if the patient claimed he or she was taking the trial medication. In the "low dose" group (300 mg aspirin in the morning) this test proved unreliable, probably because many patients collected overnight urine before taking the morning tablets. Compliance was therefore tested only in the "high dose" group (it was hardly likely to have been less in the "low dose" group) and contamination with non trial aspirin in the "placebo" group. From 1985-86 most surviving patients had a venous blood sample taken which was mailed to Oxford for further analysis, blind to treatment allocation, including haematocrit and plasma urea levels. Ruptured aortic aneurysm death was used for those patients who had necropsy or operative confirmation.
Statistical analysis
Other ischaemic heart disease death was a category for patients whose deaths were probably due to ischaemic heart disease although there was no evidence of definite myocardial infarction, and they did not die suddenly. These patients usually died of cardiac failure and were known to have ischaemic heart disease on the basis of the history and possibly necropsy examination.
The United Kingdom transient ischaemic attack ( UK-TIA) aspirin trial: Final results Gastrointestinal haemorrhage deaths were those that were clearly a result of gastrointestinal bleeding.
Other vascular deaths were patients thought to have died as a result of a vascular event but who could not be placed in any of the other categories. This category included one patient with pulmonary embolism with no underlying cause, two with cardiac valvular disease, and patients in whom there was no information other than a death certificate diagnosis of stroke, myocardial infarction or some other vascular event.
Non vascular deaths included those patients who definitely died of some disorder unrelated to vascular disease, often cancer.
Unknown was a small category where we had no useful information at all on the cause of death.
Coronary events included fatal and non-fatal myocardial infarction, sudden death with or without necropsy examination, and other ischaemic heart disease death.
Vascular deaths included all deaths which were not definitely non vascular, that is, fatal stroke, fatal myocardial infarction, sudden death, ruptured aortic aneurysm, other ischaemic heart disease death, other vascular death, fatal gastrointestinal haemorrhage-and unknown cause of death. It was important that the last two categories were included in the fundamental analyses so that they covered deaths due to the complication of treatment, and deaths which might have been vascular and therefore amenable to treatment; this strategy provides a conservative estimate of any benefit of aspirin.
Results
Of the 2449 patients that were randomised, 11 were soon found to have intracranial tumours thought to have caused their focal neurological symptoms (table 1) . "Blind to treatment" allocation, they were withdrawn from formal follow up and analysis. However, at the end of the trial six were known to be still alive and five had died from their tumours: two in the "high dose" group, two in the "low dose" group, and one in the "placebo" group. None of these patients with tumours was known to have had a stroke or myocardial infarction. Three randomisations were void since they were given in error to the wrong patients. Therefore, 2435 patient results were available for analysis and none was lost to follow up, which continued from one to seven years (mean about four); there were 3428 patient years offollow up in the "high dose" group, 3516 in "low dose" group, and 3581 in the "placebo" group (total 10 525). There were some minor protocol deviations (table 1), but these were not considered sufficient to withdraw the patient from follow up or from the analysis. During the trial follow up it became clear that 13 patients almost certainly had never had TIAs or minor strokes but they were still kept on follow up and included in the analysis (migraine, giant cell arteritis, transient global amnesia, partial seizures, micturition syncope). (8) 60 (7) 61 (7) Aspirin 126 (15) 115 (14) 120(15) Dipyridamole 51 (6) 46 (6) 35 (4) Anticoagulants 5 (1) 6 (1) 3 (0) Lipid lowing drugs 4 (0) 3 (0) 3 (0) Previous carotid endarterectomy 22 (3) 15 (2) 12 (1) Baseline characteristics The three groups were well matched (tables 2-5), particularly for all the known and important prognostic variables for stroke and myocardial infarction recorded at trial entry. There were slightly more hyperlipidaemic patients in the "low dose" than in the "high dose" aspirin group (38% versus 32%, p < 0 05) but the mean plasma cholesterol levels were almost identical (6.1 versus 6-0 mM/litre); cardiac valvular disease was slightly less common in the aspirin groups taken together than in the placebo group (1-8% versus 3 3% p < 0 05) but the absolute percentage difference was very small and mostly accounted for by aortic sclerosis and mitral leaflet prolapse which are both of dubious embolic significance; only amaurosis fugax was somewhat less common in the placebo group than in the combined aspirin (7) 48 (6) 20 (2) Abdominal flatulence 4 (0) irin 300 mg) In the "placebo" group there were about three gastrointestinal haemorrhages per thousand patient years of follow up, in the "low dose" group about seven, and in the "high dose" group about 1 1; this was a clearcut dose response effect. The odds ratio for gastrointestinal haemorrhage comparing the "high-dose" *~'with the "low dose" aspirin groups was (95% CI 0-942-79, fig 2) and comparing the "low dose" with the "placebo" group was (95% CI 1 20-553). Less *Numbers in brackets are the number of patients not on trial medication at the time of the bleed; they are, however, included in the non-bracketed numbers (that is, 73 patients had a bleed although 15 of them were not on trial medication at the time). No patient had more than one bleeding episode.
tThis contributed to the death of the patient, but was not the underlying cause which was cerebral infarction due to carotid endarterectomy. Note the comparisons were made only for patients alive in 1985/86 and for whom a blood sample was available (in about 10% a blood sample was forgotten, broke in the post, or was unsuitable for analysis).
During the follow up there was a highly statistically significant increase in the mean blood urea which was very similar in all three treatment groups (table 9); this increase was less in the "low dose" aspirin than in the "placebo" group. Presumably, this change was a reflection of increasing age. There was also a statistically significant but very small decrease in the mean haematocrit in all three groups. This decrease was lowest in the "high-dose" group and equal in the "placebo" and "lowdose" groups ( 3) . The general fall in pressure may have been due to a combination of regression to the mean, treatment as a consequence of repeated surveillance and therefore a high chance of detecting hypertension, and also to repeating the measurement in familiar surroundings.
Major events
All major vascular events of interest and all non-vascular deaths in the patients during follow up, irrespective of compliance with trial medication, are shown in tables 11 and 12 for males, females and both sexes combined, and for "high-dose" aspirin, "low-dose" aspirin and "placebo". These events were often not mutually exclusive; many patients had more than one (for example, minor stroke followed by non-fatal myocardial infarction followed by non-vascular death).
"High-dose" versus "low-dose" aspirin For all categories and combinations of event (with one exception) there were no statistically significant differences between the two dose (table 13 and fig 2) . Although all the confidence intervals were fairly wide almost all Aspirin ("high-dose" and "low-dose") versus placebo: all patients (fig 4) This is our preferred analysis because on the basis of the above results (table 14) and the overview of all similar trials we were not convinced that the response to aspirin was definitely different in males and females. The 
Fatal stroke Definite haemorrhage
Fatal ischaemic heart disease (IHD) Myocardialinfarction 11 ( 1 8 we should have sought wider collaboration not just in the UK, but also in Europe. Although somewhat imprecise, the trial results are unbiased by any important baseline inequality between the three groups of patients and by any knowledge of the treatment allocation of individual patients during follow up and assessment of the events analysed. Although there were more complaints of upper gastrointestinal symptoms from those subjects taking aspirin (than those on placebo), the difference was not so great that it would have affected the "blinding" of either patients or collaborating neurologists. In any event, the clinical audit committee had no knowledge of any adverse effects when examining the validity of the analysable events in individual patients.
This trial is the only one to have compared directly 1200 mg with 300 mg daily of aspirin. There can be no doubt that the higher dose was more gastrotoxic, producing mild but irritating upper gastrointestinal symptoms and almost certainly gastrointestinal haemorrhage as well. Presumably dispersible, soluble, or enteric coated aspirin 300 mg daily would have caused less than the approximate 19% increase in mild gastric adverse effects, and the two to three fold increase in the risk of gastrointestinal haemorrhage that we observed compared with placebo. Given the reversibility of the mild adverse effects and the very low mortality and negligible long term morbidity of gastrointestinal haemorrhage, this seems a small price to pay for the approximate 25% reduction in the risk of serious vascular events evident from the overview analysis.2 There was no obvious dose response relationship for constipation and bruising, nor for intracranial haemorrhage. Whether aspirin definitely causes or precipitates intracranial haemorrhage is a question that will only be answered reliably from the next phase of the overview analysis rather than on the basis of the small numbers reported here.
If doses lower than 300 mg daily of aspirin are shown to be as effective, then maybe the risk-benefit balance would be even more in favour of aspirin; the cost is already so low that it is almost not worth considering (approximately £1.46 per annum for 300 mg soluble aspirin daily, according to the British National Formulary).
We believe that the results of this trial, and other similar unconfounded trials included in the Antiplatelet Trialists' Collaboration overview, can be generalised to individual patients with transient ischaemic attacks, mild ischaemic strokes, and possibly more major ischaemic strokes. This is because qualitatively, all are similar in terms of their underlying arterial pathology; most patients have atheroma but a small proportion have an embolic source in the heart. For the latter it may eventually transpire that anticoagulation with warfarin is more effective than aspirin.
It may be reasonable to start aspirin treatment as soon as patients present to medical attention, but whether it is safe to do so in a stroke patient before intracerebral haemorrhage is excluded by an early CT scan is uncertain. However, there is no doubt that this question could and should be answered in a large scale trial of aspirin, not for secondary prevention but for the treatment ofacute stroke within hours of onset. Naturally, for any individual transient ischaemic attack or stroke patient it is impossible to know exactly what the risk of a future serious vascular event will be and exactly how much the risk will be reduced by aspirin. However, on balance, the effect of aspirin is likely to be favourable, provided it is avoided in patients with obvious contraindications, such as, an active peptic ulcer.
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